Linagliptin, a selective dipeptidyl peptidase-4 (DPP-4) inhibitor that was originally discovered as an antidiabetic drug for treating type 2 diabetes mellitus, was able to restore critical proteins and the balance between autophagy and apoptosis. Here, DPP4 is linked to diabetes mellitus.